JP2024096688A5 - - Google Patents

Info

Publication number
JP2024096688A5
JP2024096688A5 JP2024027308A JP2024027308A JP2024096688A5 JP 2024096688 A5 JP2024096688 A5 JP 2024096688A5 JP 2024027308 A JP2024027308 A JP 2024027308A JP 2024027308 A JP2024027308 A JP 2024027308A JP 2024096688 A5 JP2024096688 A5 JP 2024096688A5
Authority
JP
Japan
Prior art keywords
antibody
cells
cell
baff
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024027308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024096688A (ja
JP7778831B2 (ja
Filing date
Publication date
Priority claimed from JP2019516100A external-priority patent/JP7275446B2/ja
Application filed filed Critical
Publication of JP2024096688A publication Critical patent/JP2024096688A/ja
Publication of JP2024096688A5 publication Critical patent/JP2024096688A5/ja
Priority to JP2025199127A priority Critical patent/JP2026048672A/ja
Application granted granted Critical
Publication of JP7778831B2 publication Critical patent/JP7778831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024027308A 2016-06-06 2024-02-27 Ｂａｆｆ－ｒ抗体及びその使用 Active JP7778831B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025199127A JP2026048672A (ja) 2016-06-06 2025-11-19 Ｂａｆｆ－ｒ抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346324P 2016-06-06 2016-06-06
US62/346,324 2016-06-06
JP2019516100A JP7275446B2 (ja) 2016-06-06 2017-06-06 Ｂａｆｆ－ｒ抗体及びその使用
PCT/US2017/036181 WO2017214170A2 (en) 2016-06-06 2017-06-06 Baff-r antibodies and uses thereof
JP2022017156A JP7448299B2 (ja) 2016-06-06 2022-02-07 Ｂａｆｆ－ｒ抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022017156A Division JP7448299B2 (ja) 2016-06-06 2022-02-07 Ｂａｆｆ－ｒ抗体及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025199127A Division JP2026048672A (ja) 2016-06-06 2025-11-19 Ｂａｆｆ－ｒ抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2024096688A JP2024096688A (ja) 2024-07-17
JP2024096688A5 true JP2024096688A5 (https=) 2025-08-27
JP7778831B2 JP7778831B2 (ja) 2025-12-02

Family

ID=59325613

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019516100A Active JP7275446B2 (ja) 2016-06-06 2017-06-06 Ｂａｆｆ－ｒ抗体及びその使用
JP2022017156A Active JP7448299B2 (ja) 2016-06-06 2022-02-07 Ｂａｆｆ－ｒ抗体及びその使用
JP2024027308A Active JP7778831B2 (ja) 2016-06-06 2024-02-27 Ｂａｆｆ－ｒ抗体及びその使用
JP2025199127A Pending JP2026048672A (ja) 2016-06-06 2025-11-19 Ｂａｆｆ－ｒ抗体及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019516100A Active JP7275446B2 (ja) 2016-06-06 2017-06-06 Ｂａｆｆ－ｒ抗体及びその使用
JP2022017156A Active JP7448299B2 (ja) 2016-06-06 2022-02-07 Ｂａｆｆ－ｒ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025199127A Pending JP2026048672A (ja) 2016-06-06 2025-11-19 Ｂａｆｆ－ｒ抗体及びその使用

Country Status (5)

Country Link
US (3) US11136405B2 (https=)
EP (2) EP4628094A3 (https=)
JP (4) JP7275446B2 (https=)
CN (2) CN109641957B (https=)
WO (1) WO2017214170A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
IL308798A (en) * 2016-06-06 2024-01-01 Univ Texas Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
EP4628094A3 (en) 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CN121405815A (zh) * 2018-12-19 2026-01-27 希望之城 Baff-r双特异性t细胞衔接子抗体
CN113874391B (zh) 2019-02-20 2025-10-28 希望之城公司 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN111499723B (zh) * 2020-05-28 2021-04-09 广州百暨基因科技有限公司 一种嵌合抗原受体及其应用
WO2022031568A1 (en) * 2020-08-04 2022-02-10 Novartis Ag Treatment of cll
AU2021320129B2 (en) * 2020-08-04 2025-12-18 Novartis Ag Treatment of B cell malignancies
CN114149504B (zh) * 2020-09-07 2024-01-12 白先宏 Baff-r结合分子及其应用
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
TW202300520A (zh) * 2021-05-19 2023-01-01 大陸商上海詩健生物科技有限公司 特異性識別baff-r的嵌合抗原受體分子及其應用
AR127163A1 (es) * 2021-09-29 2023-12-27 Dragonfly Therapeutics Inc Anticuerpos dirigidos a baff-r y uso de estos
EP4558522A1 (en) * 2022-07-19 2025-05-28 Novartis AG Treatment of aiha with baff or baff receptor inhibitory antibodies
CN116041515A (zh) * 2022-09-20 2023-05-02 南京驯鹿医疗技术有限公司 一种靶向baff-r抗原的全人源抗体、单链抗体、抗原结合片段
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
WO2025067496A1 (zh) * 2023-09-28 2025-04-03 南京驯鹿生物技术股份有限公司 靶向baff-r的全人源抗体、car-t细胞及其应用
CN117783521B (zh) * 2023-11-23 2025-03-04 中国农业科学院兰州兽医研究所 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒
WO2026007893A1 (zh) * 2024-07-01 2026-01-08 应世生物科技(南京)有限公司 一种靶向整合素α3β1的抗体或其抗原结合片段及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CN100447244C (zh) * 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
SI2315780T1 (sl) * 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
WO2011119901A1 (en) * 2010-03-26 2011-09-29 Alnylam Pharmaceuticals, Inc. Gene amplification and transfection methods and reagents related thereto
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
JP6158865B2 (ja) 2015-06-30 2017-07-05 株式会社リクルートホールディングス 顧客情報提供システム及びその制御方法並びにコンピュータプログラム
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP4628094A3 (en) 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2024096688A5 (https=)
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
JP2025166058A5 (https=)
JP2021531005A5 (https=)
JP2020522513A5 (https=)
JP2020531043A5 (https=)
JP2024119853A5 (https=)
JP2026041845A5 (https=)
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
JP2024024114A5 (https=)
JP2024541680A5 (https=)
JP2024534265A5 (https=)
JP7731979B2 (ja) 特異性が増強した二重特異性抗体（ｓｅｂａ）
JP2024540148A5 (https=)
JP2020522562A5 (https=)
JP2024532886A5 (https=)
JP7720989B2 (ja) Ｅｇｆｒ及びｈｅｒ３を標的とする二重特異性四価抗体
JP2024509501A5 (https=)
JP2023533793A5 (https=)
JP2023541455A5 (https=)
JP2024543822A5 (https=)
JP2024533457A5 (https=)
JP2022527790A5 (https=)
JP7641292B2 (ja) 抗ｃｄ１９抗体、その使用方法及び製造方法
JP2024508597A5 (https=)